dibekacin and Infant--Newborn--Diseases

Once a day of arbekacin (ABK) administrations based on a new object of peak concentration setting on 9-20 microg/mL were performed to 14 neonates. The gestational ages were 27.3 +/- 4.2 weeks. As to the preparing initial dosage, Therapeutic Drug Monitoring Program soft was used. Mean daily dose of 6.2 +/- 0.4 mg/kg bodyweight was administered every 24 to 48 h by 30 min intravenous infusion. Mean serum peak concentrations of ABK and those of trough concentrations were 15.2 +/- 4.3 microg/mL and 2.0 +/- 1.4 microg/mL respectively. The relationship between the measured values (y) and predicted values (x) showed the regression equation y = 0.969 + 0.931x (R2 = 0.769, n = 35), which suggested the usefulness of the dosage design. Overall clinical effectiveness was 78.9% (11/14). There were no obvious adverse effects including abnormal auto auditory brainstem responses and serum creatinine increase. Effectiveness rate and no adverse effects suggested that once a day of ABK therapy in neonate including extremely preterm infant was preferable regimen.

Topics: Anti-Infective Agents; Dibekacin; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, Diseases; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections

Topics: Audiometry; Audiometry, Evoked Response; Dibekacin; Female; Half-Life; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Kanamycin; Kinetics; Male

Topics: Birth Weight; Dibekacin; Humans; Infant, Newborn; Infant, Newborn, Diseases; Injections, Intramuscular; Injections, Intravenous; Kanamycin; Kinetics